Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative status confers therapeutic sensitivity to Paclitaxel, Pembrolizumab in patients with Invasive Breast Carcinoma.
This statement is based on a regulatory approval from the Health Canada:
KEYTRUDA (pembrolizumab), in combination with chemotherapy, is indicated for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumours express PD-L1 (Combined Positive Score [CPS] ≥ 10) as determined by a validated test.